Biomarin Pharmaceutical Aktie
62,34
EUR
+0,18
EUR
+0,29
%
64,99
USD
+0,32
USD
+0,49
%
Biomarin Pharmaceutical Aktie Analyse
| 14.12.18 | Biomarin Pharmaceutical Outperform | Wolfe Research | |
| 01.10.18 | Biomarin Pharmaceutical Overweight | Cantor Fitzgerald | |
| 07.08.18 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
| 03.08.18 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
| 16.05.18 | Biomarin Pharmaceutical Buy | Canaccord Adams | |
| 15.09.17 | Biomarin Pharmaceutical Sector Perform | RBC Capital Markets | |
| 14.07.17 | Biomarin Pharmaceutical Outperform | BMO Capital Markets | |
| 30.03.17 | Biomarin Pharmaceutical Neutral | UBS AG | |
|
Werbung
|
|||
| 02.03.17 | Biomarin Pharmaceutical Neutral | Instinet | |
| 08.12.16 | Biomarin Pharmaceutical Buy | Gabelli & Co | |
| 03.11.16 | Biomarin Pharmaceutical Buy | Deutsche Bank AG | |
| 08.04.16 | Biomarin Pharmaceutical Outperform | BMO Capital Markets | |
| 08.03.16 | Biomarin Pharmaceutical Outperform | Robert W. Baird & Co. Incorporated | |
| 03.03.16 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
| 29.02.16 | Biomarin Pharmaceutical Neutral | Wedbush Morgan Securities Inc. | |
| 26.02.16 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
| 25.11.15 | Biomarin Pharmaceutical Perform | Oppenheimer & Co. Inc. | |
| 08.07.15 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
| 19.06.15 | Biomarin Pharmaceutical Neutral | Robert W. Baird & Co. Incorporated | |
| 18.06.15 | Biomarin Pharmaceutical Buy | Deutsche Bank AG | |
| 18.06.15 | Biomarin Pharmaceutical Buy | Canaccord Adams | |
| 18.06.15 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
| 05.06.15 | Biomarin Pharmaceutical overweight | Barclays Capital | |
| 27.03.15 | Biomarin Pharmaceutical Buy | UBS AG | |
| 27.03.15 | Biomarin Pharmaceutical Buy | Deutsche Bank AG | |
| 19.12.14 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
| 11.12.14 | Biomarin Pharmaceutical Buy | UBS AG | |
| 25.11.14 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
| 24.10.14 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
| 06.11.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 03.09.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 28.08.12 | Biomarin Pharmaceutical hold | Deutsche Bank Securities | |
| 23.07.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 22.06.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 01.06.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 17.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 13.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
| 12.12.11 | Biomarin Pharmaceutical buy | Citigroup Corp. | |
| 08.12.11 | Biomarin Pharmaceutical buy | Citigroup Corp. | |
| 07.12.11 | Biomarin Pharmaceutical buy | Jefferies & Company Inc. | |
| 29.09.11 | Biomarin Pharmaceutical buy | Deutsche Bank Securities | |
| 25.10.10 | Biomarin Pharmaceutical neutral | Wedbush Morgan Securities Inc. | |
| 17.08.10 | Biomarin Pharmaceutical neutral | Wedbush Morgan Securities Inc. | |
| 16.04.10 | Biomarin Pharmaceutical kaufen | Der Aktionär | |
| 29.10.09 | Biomarin Pharmaceutical outperform | Credit Suisse Group | |
| 22.10.09 | Biomarin Pharmaceutical buy | Citigroup Corp. | |
| 19.10.09 | Biomarin Pharmaceutical hold | ROTH Capital Partners, LLC | |
| 08.10.09 | Biomarin Pharmaceutical buy | Jefferies & Company Inc. | |
| 03.08.09 | Biomarin Pharmaceutical neutral | Wedbush Morgan Securities Inc. | |
| 31.07.09 | Biomarin Pharmaceutical buy | Jefferies & Company Inc. | |